期刊
ANTI-CANCER DRUGS
卷 28, 期 7, 页码 815-817出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CAD.0000000000000521
关键词
cardiotoxicity; gynecologic malignancy; long-term chemotherapy; pegylated liposomal doxorubicin; safety
Pegylated liposomal doxorubicin (PLD) is used widely in gynecologic oncology and other oncology disciplines. Native doxorubicin use is associated with the potential for significant toxicity. Cardiac toxicity in particular limits lifetime dose. PLD has not been shown to be associated with clinical cardiac toxicity. We report on the long-term use of PLD in a patient with recurrent high-grade serous ovarian cancer to a lifetime dose of 4600mg/m(2). This therapy was associated with long-term stable disease, good performance status, and minimal adverse effects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据